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Interleukin-18 (IL-18), a proinﬂammatory cytokine, is produced by oral epithelia and carcinoma cells and implicated in tu-
mor regression. Since its direct biological eﬀect on oral cancer cells is not well deﬁned, in this study, we employed a KB cell
line to test IL-18 activity. Recombinant human IL-18 signiﬁcantly inhibited KB cell proliferation in a dose-dependent fashion
(P<. 05) without increasing cytotoxicity. Analysis of its mode of action showed that IL-18 induced cell cycle arrest in the S
phase; however, it did not trigger apoptotic cell death. Findings in this study indicate that the suppression of KB cell prolif-
eration was attributed to the modulation of cell cycle progression, providing a new role of this cytokine in antitumor mecha-
nisms.
Copyright © 2006 A. Nilkaeo and S. Bhuvanath. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
INTRODUCTION
Interleukin-18 (IL-18) is a pleiotropic inﬂammatory cy-
tokine produced by both immune and nonimmune cells. It
shares several properties with a proinﬂammatory cytokine
IL-1, and is therefore categorized as a member of the IL-1
family. This cytokine was ﬁrst discovered as a potent IFN-
γ-inducing factor in the serum and livers of mice exposed
to Propionibacterium acnes and LPS [1]. The known activa-
tors of IL-18 production are LPS, IL-1, IL-6, TNF-α, and in-
terferons. IL-18 is initially produced as pro-IL-18 (24kDa)
which is then processed by caspase-1 and other caspases to
a mature form with a molecular weight of 18kDa [2]. IL-18
exerts its biological eﬀect via its receptor complex. IL-18 re-
ceptor (IL-18R) is comprised of IL-18Rα which is identical
to the IL-1R-related protein (IL-1Rrp) and a signal trans-
ducing subunit IL-18Rβ. The binding of IL-18 to its re-
ceptor results in recruitment of adaptor proteins such as
MyD88, IRAK, and TRAF6 and leads to the increased acti-
vation of transcription factor NF-κB[ 3, 4]. It also activates
AP-1, MAPK, STAT3, and the stress kinase p38 pathways
[5].
IL-18 modulates both innate and speciﬁc immune re-
sponses [6]. IL-18 and IL-12 act synergistically to induce
IFN-γ production by T cells, and it can synergize with IL-10
to induce IFN-γ production by NK cells [7, 8]. In addition,
IL-18 is involved in inﬂammatory responses of some au-
toimmunity conditions including arthritis and systemic lu-
pus erythematosus (SLE) [9, 10]. It is also expressed at the
maternal-fetal interface and function to enhance decidual
lymphocyte cytotoxic activity [11]. With its primary func-
tion in activation of NK cells and induction of IFN-γ pro-
duction by T cells, several recent studies have shown that IL-
18 is a potential player in modulating the immune system to
destroy cancer cells [12].
In human oral carcinoma, patients often display high an-
tibody functions and high levels of Th2 cytokines from an
advanced-stage tumor [13]. IL-18 is produced by oral ep-
ithelia and carcinoma and this cytokine may function to en-
hance IFN-γ production by NK cells [14]. Furthermore, sera
levels of IL-18 as well as other Th1 cytokines are upregu-
lated in nude mice bearing salivary adenocarcinoma treated
with streptococcal product and this results in a signiﬁcant
reduction of tumor growth [15]. In addition, it was demon-
strated that polymorphonuclear leukocyte production of IL-
18 was enhanced in oral cavity cancer patients after cancer
treatment [16]. These data indicate that IL-18 is an anti-
neoplastic cytokine. However, an antitumor property of IL-
18 on oral carcinoma has not been directly shown. In this
study, we have chosen the KB oral carcinoma cell line, as
an example of oral carcinoma, to study the eﬀect of IL-
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MATERIALS AND METHODS
Cytokinesandcellline
Recombinant human IL-18, IL-1β,a n dT N F - α were pur-
chased from Peprotech Inc (Rocky Hill, NJ). The KB cell line
is a carcinoma cell line derived from the oral cavity and was
kindly provided by Dr Sithichai Khuntongkaew, Faculty of
Dentistry, ThammasatUniversity, Thailand. The cellsdisplay
epithelialmorphology.ThecellsweremaintainedinDMEM-
F12 (Life Technologies, Gaithersburg, Md) with 10% FBS
(Biochrom AG Seromed, Berlin, Germany) and antibiotics
(100 unit/mL of penicillin G and 100μg/mL of streptomycin
sulfate) and cultured at 37◦Ci n5 %C O 2.
ExpressionofIL-18Randapoptoticgenes
The expression of IL-18 receptors and apoptotic genes in
KB cells was investigated using RT-PCR. Cells were cultured
in complete DMEM-F12 medium with or without cytokine
treatment. The total RNA was isolated from KB cells by us-
ing an acid-guanidium thiocyanate phenol/chloroform ex-
traction protocol [17], and examined for purity using 1%
denaturing agarose gel electrophoresis, and then subjected to
one-step RT-PCR (Qiagen,Hilden, Germany) for the expres-
sion of genes that paralleled the G3PDH house keeping gene.
Thefollowingspeciﬁcoligonucleotideprimerswereused:IL-
18Rα upstream (5  GTTGAGTTGAATGACACAGG 3 )a n d
IL-18Rα downstream (5  TCCACTGCAACATGGTTAAG 3 )
generating a 420-bp PCR product; IL-18Rβ upstream (5 
TGCTCCTGTACATCCTGCTTG 3 ) and IL-18Rβ down-
stream(5  TCTGCTCAGCAACATCTCTAT3 )generatinga
783-bp PCR product; G3PDH upstream (5  TGAAGGTCG-
GAGTCAACGGATTTGGT3 )andG3PDHdownstream(5 
CATGTGGGCATGAGGTCCACCAC 3 ) generating a 983-
bp PCR product; bax upstream (5  GGCCCACCAGCTCT-
GAGCAGA 3 ) and bax downstream (5  GCCACGTGGGC-
GTCCCAAAGT 3 ) generating a 479-bp PCR product; bcl-2
upstream (5  GTGGAGGAGCTCTTCAGGGA 3 )a n db c l -
2d o w n s t r e a m( 5   AGGCACCCAGGGTGATGCAA 3 )g e n -
erating a 304-bp PCR product. Ampliﬁcation of cDNA was
performed for 32 cycles at 94◦C for 30s, 58◦C for 30s, and
72◦C for 30s for IL-18Rα and IL-18Rβ; 35 cycles at 94◦C
for 45s, 60◦Cf o r4 5s ,a n d7 2 ◦C for 2min for G3PDH; 35
cycles at 94◦C for 30s, 62◦Cf o r3 0s ,a n d7 2 ◦C for 30s for
bax; and at 94◦C for 30s, 60◦Cf o r3 0s ,a n d7 2 ◦Cf o r3 0s
for bcl-2. PCR products were examined by 1.2% agarose gel
electrophoresis in 0.5X Tris-borate-EDTA (TBE) buﬀer, and
visualized by ethidium bromide staining.
MTTproliferationassayandlactate
dehydrogenaseassay
Brieﬂy, KB cells (10000 cells/well) were cultured in colla-
gen I (50μg/mL) coated 96-well culture plates, in a total
volume of 200μL DMEM-F12 supplemented with 1% FBS.
Cells were cultured in the presence of increasing concen-
trations of recombinant human IL-18 (0–100ng/mL). Both
treatment and control groups were performed in 6–8 repli-
cate wells. The relative number of viable cells was then deter-
mined at 72 hours after incubation, by adding 1mg/mL of
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide (MTT) and incubating the cell further for 4 hours. The
formazancrystalsformedwerethensolubilizedwithacidiso-
propanol for 1 hour. The absorption value of the solution at
595nm directly represents relative cell numbers. The cell de-
crease percent relative to the control group was then deter-
mined.
Lactate dehydrogenase (LDH) released from the cells was
used to detect cytotoxicity and was measured at the end of
each proliferation experiment. Brieﬂy, culture plates were
centrifuged at 1500rpm for 15 minutes at room temperature
to ensure accumulation of cells at the bottom of the wells.
Cell-free culture media (100μL)wascollectedandthenincu-
bated with 100μL of the reaction mixture of the cytotoxicity
detection kit (Boehringer Mannheim, Indianapolis, Ind) for
30minutesatr oomtemperatur einthedark.1NHCl(50μL)
was added into each well to stop the enzymatic reaction. The
opticaldensityofthesolutionwasthenmeasuredbyusingan
ELISA plate reader with a 490nm ﬁlter. Cytotoxicity percent
to the control was then determined.
Celldeathassays
For the in situ apoptotic cell death detection assay, KB cells
were cultured on a glass slide in 6-well plate until 70–80%
conﬂuence had been achieved. The culture medium was re-
placed with fresh medium containing 1% FBS with or with-
out IL-18 (100ng/mL) and incubated for 72 hours. Apop-
totic cell death was detected using an apoptosis staining kit
(R&D systems, Minneapolis, Minn) in the culture plate and
visualized using laser confocal microscopy. Similar exper-
iments were conducted without glass slides and apoptotic
cells were determined using ﬂow cytometry.
In DNA laddering analysis, KB cells were cultured in 6-
wellcultureplateuntil70–80%conﬂuence.Themediumwas
replaced with fresh medium supplemented with 1% FBS in
the presence of IL-18 (0–100ng/mL) and incubated for 24,
48, and 72 hours. Cells were then washed with cold PBS and
lysis solution was added. DNA samples were then extracted
from the solution using a phenol-chloroform-isoamyl alco-
hol extraction protocol. DNA concentration was determined
using a spectrophotometer (OD260). DNA (1μg) samples
were then fractionated by agarose gel (1.5%) electrophore-
sis. The gel was then stained with ethidium bromide and vi-
sualized using a UV transilluminator, and photographs were
taken using a gel documentation system.
Cellcycleanalysis
KB cells (350000 cells/well) were grown in 6-well culture
plate and synchronized using serum starvation and hydrox-
yurea (0.1mM) treatment for 24 hours. Synchronized KB
cells were restimulated with medium containing 2% FBS or
2% FBS plus IL-18 (100ng/mL) and incubated for various
times(0,8,24,32,and48hours).Cellswerethentrypsinized,A. Nilkaeo and S. Bhuvanath 3
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Figure 1: Expression of IL-18 receptors and biological activity of IL-18 on KB cells. (a) Two μg of total RNA samples from KB cells, with
or without cytokines treatment, were subjected to RT-PCR for IL-18R mRNA expression. (b) KB cells were cultured for 72 hours in media
containing increasing concentrations of IL-18. Relative cell numbers were measured by MTT assays and the relative cell decrease (mean
± SEM) was then determined. (c) Cytotoxicity of IL-18 was determined at the end of the proliferation assay using an LDH detection kit.
Asterisk (∗, P<. 05) represents signiﬁcant diﬀerence between the treatment and control groups as analyzed by one-way ANOVA.
centrifuged, and resuspended in PBS. Cells were then ﬁxed,
stained with propidium iodide solution, and processed for
ﬂow cytometry analysis. The cell percent in each cell cycle
phase was determined in each sample (30000 counts), and
comparison was made between the 2 groups.
Statisticalanalysis
Data are presented as means ± standard error of the mean
(SEM). In cell proliferation and cytotoxicity experiments,
Dunnett’s method of one-way analysis of variance (ANOVA)
was used to assess diﬀerences among control groups and
treatment groups. Diﬀerences in data between two groups in
the cell cycle studies were analyzed using the Student t test.
All experiments were repeated at least three times for repro-
ducibility.
RESULTS
ExpressionofIL-18Randbiologicalactivityof
IL-18onKBcells
Expression of IL-18R was investigated under normal culture
condition and in the presence of IL-18 (10ng/mL), TNF-
α (10ng/mL), or IL-1β (10ng/mL), separately or in vari-
ous combinations for 24 hours. In normal conditions, with-
out cytokine stress, (Figure 1(a)) KB cells constitutively ex-
pressed IL-18-receptor (both IL-18Rα and IL-18Rβ)t r a n -
scripts. However, IL-18R expression was regulated with cy-
tokine treatment. By normalization of the band intensity
of each gene to that of G3PDH, IL-18Rα expression was
augmented by IL-18 alone or in combination with TNF-α.
In contrast, TNF-α alone, IL-18 plus IL-1β, and IL-18 plus
TNF-α down-regulated IL-18Rβ expression. Results from
thisexperimentclearlyindicatedthattheKBcelllineisaspe-
ciﬁc target for IL-18 by regulating the expression of IL-18R.
To test the biological eﬀect of IL-18 on KB cells, we
utilized nonradioactive MTT assays. IL-18 treatment in KB
cells (Figure 1(b)) resulted in suppression of cell prolifera-
tion in a dose-dependent fashion. As low as 10pg/mL, IL-
18 caused a 10% reduction of cell numbers compared to
the control group (P<. 05). At the highest concentration
(100ng/mL) of cytokine used in this study, the decrease of
cell numbers reached a maximum of 19%. No further de-
crease of cell numbers occurred when the IL-18 dose was
doubled to 200ng/mL. Further analysis on IL-18 cytotox-
icity, by measuring LDH release from KB cells at the end
of each proliferation experiment, interestingly, showed no
signiﬁcant concentration-dependent changes in LDH level
(Figure 1(c)). This indicated that the inhibition of KB cell
proliferation was not mediated by the induction of cytotoxi-
city.
InvolvementofIL-18oncelldeath
To further study the involvement of IL-18 on cell death, we
employed 2 techniques that are capable of illustrating DNA
fragmentation in apoptotic cells. In detection of in situ cell
death, treatment of KB cells with IL-18 resulted in no sig-
niﬁcant induction of apoptotic cell death compared to the
nontreatment group (Figures 2(b) and 2(c)). This experi-
ment was conﬁrmed by using the ﬂow cytometric method.
There was no signiﬁcant diﬀerence in mean ﬂuorescent in-
tensity between the nontreated control group and the IL-18
treated group (data not shown). In the DNA laddering anal-
ysis (Figure 2(d)), fragmented DNA was not observed in KB
cells treated with IL-18 after 24, 48, or 72 hours. In addition,
spontaneous cell death could not be demonstrated by DNA
laddering. This result is consistent with the in situ apoptotic
cell death detection assay, indicating that IL-18 treatment (in
the dose range from 0.01–100ng/mL) of KB cells did not
trigger apoptotic cell death. In addition, analysis of apop-
totic gene expression in KB cells treated with IL-18 at various
time points was also conducted using RT-PCR. Normaliza-
tion of the band intensities of bcl-2 and bax gene to that of4 Mediators of Inﬂammation
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Figure 2: Involvement of IL-18 in apoptotic cell death of KB cells. KB cells were cultured for 48 hours on slides, with or without IL-18. Cells
were then subjected to the in situ cell death detection assay. Apoptotic cells, with a ﬂuorescent nucleus, were visualized using laser confocal
microscopy. (a) Positive staining control, (b) nontreatment control, (c) IL-18 (100 ng/mL) treatment. In the DNA laddering analysis (d),
DNA samples were extracted from KB cells cultured with or without IL-18 (0–100ng/mL) treatment and fractionated by agarose gel (2%)
electrophoresis. (e) Total RNA (2μg) samples from KB cells, with or without IL-18 (10ng/mL) treatment, were subjected to RT-PCR for
expression of apoptotic genes (bcl-2 and bax) along with the gene for G3PDH.
G3PDH was used to determine the level of expression. As we
anticipated (Figure 2(e)), the expression of these genes was
not altered by IL-18 (10ng/mL) treatments at any time point
tested, suggesting that IL-18 was not involved in altering the
expression of apoptotic genes in KB cells.
IL-18modulationofcellcycleprogression
Since the inhibitory eﬀe c to fI L - 1 8o nK Bc e l l sw a sn o td u e
to the induction of cell death, we therefore hypothesized that
inhibition could be attributed to the modulation of cell cycle
progression. To examine the eﬀect of IL-18 on the control of
KB cell cycle progression, the numbers (%) of cells in each
stage (G0/G1, S, and G2/M) of the cell cycle of both control
group and treatment group were compared. We found that
the majority of synchronized cells (approximately 65%) were
arrested in the S phase, leaving a small number of cells in
the G2/M phase (approximately 5%). Within 8 hours of res-
timulation by 2% FBS, cells were released from their S phase
arrest (Table 1). However, in the presence of IL-18, the cell
cycle progression was delayed. The number of cells that ex-
ited the S phase was lower in the cytokine treated group
compared to the control (P<. 001). At 24 hours after cell
cycle restimulation, the number of cells in the S phase in
the IL-18 treated group was higher than that of the control
group (P<. 001). At 32 and 48 hours, there was no sig-
niﬁcant diﬀerence in the proportion of cells in each cell cy-
cle phase between the IL-18-treated and the control group.
Although the S phase arrest phenomenon lasted only for
the ﬁrst 24 hours, from this evidence we concluded that KB
cells do exhibit a slower proliferation rate in the presence of
IL-18.A. Nilkaeo and S. Bhuvanath 5
Table 1: Eﬀect of IL-18 on KB cell cycle progression. Synchronized KB cells were restimulated with 2% FBS, with or without IL-18
(100ng/mL). Percentage of cells (mean ± SEM) in each cell cycle phase was determined. Asterisk (∗, P<. 001) represents signiﬁcant
diﬀerence between IL-18 treatment and control groups as analyzed by T test.
Treatment
FBS
FBS
+
IL-18
8hours
G0/G1 = 39.2 ±1.7
S = 21.43 ±1.54
G2/M = 39.37 ±2.74
0 1023
FL2-area
0
16
E
v
e
n
t
s
24hours
G0/G1 = 31.73 ±0.33
S = 50.85 ±1.34
G2/M = 17.42 ±0.71
0 1023
FL2-area
0
32
E
v
e
n
t
s
32hours
G0/G1 = 55.5 ±1.35
S = 34.29 ±4.61
G2/M = 12.19 ±2.29
0 1023
FL2-area
0
64
E
v
e
n
t
s
48hours
G0/G1 = 44.68 ±0.15
S = 40.9 ±2.71
G2/M = 14.43 ±2.79
0 1023
FL2-area
0
128
E
v
e
n
t
s
G0/G1 = 31.26 ±2.17∗
S = 35.49 ±3.19∗
G2/M = 33.24 ±5.26
0 1023
FL2-area
0
32
E
v
e
n
t
s
G0/G1 = 31.82 ±0.87
S = 56.57 ±1.65∗
G2/M = 11.65 ±2.48
0 1023
FL2-area
0
32
E
v
e
n
t
s
G0/G1 = 49.79 ±0.81
S = 33.25 ±2.31
G2/M = 16.95 ±2.72
0 1023
FL2-area
0
64
E
v
e
n
t
s
G0/G1 = 44.28 ±0.49
S = 40.02 ±1.57
G2/M = 15.53 ±1.58
0 1023
FL2-area
0
128
E
v
e
n
t
s
DISCUSSION
Because of its remarkable ability to activate IFN-γ produc-
tion by immune cells and to enhance NK cell activity, IL-
18 has been identiﬁed as a good candidate for cancer im-
munotherapy. To date, there have been no reports on the di-
rect eﬀect of this cytokine on cancer cells. In this study, using
KB cells as the representative of oral carcinoma cells, we have
demonstrated, for the ﬁrst time, a direct in vitro interaction
of IL-18 with KB cells on their proliferation, cell death, and
cell cycle progression. IL-18 treatment in KB cells resulted in
a reduction of cell proliferation. Like other solid tumor stud-
ies, IL-18 was shown to exhibit its antitumor properties. In a
study of human pancreatic carcinoma cells, it was demon-
strated that during the drug treatment, cancer cells could
produce IL-18, which in turn enhanced IFN-γ production
b yTc e l l s[ 18]. This indicates that IL-18 acts as a mediator
for antitumor mechanisms. In addition, IL-18 could exert its
action in concert with other cytokines, such as IL-23, or a
nitric oxide synthase inhibitor to enhance antitumor immu-
nity [19, 20]. Interestingly, in a nonsolid tumor model, this
cytokine did not have inhibitory eﬀects, as shown in human
leukemia cell lines [21]. We have also shown that IL-18 treat-
ment did not lead to cytotoxicity or induction of apoptotic
cell death or alteration of apoptotic gene expression in KB
cells. Similarly, this phenomenon was observed in a study in
vitro IL-18 treatment of B16 mouse melanoma cell line [22].
In a mouse model of neuroblastoma, IL-18 treatment led to
tumor death, however it is likely caused by the activation of
NK cells in the tumor microenvironment, rather than the di-
rect eﬀect of IL-18 [23]. In addition, previous studies have
demonstrated that IL-18 promotion of apoptosis maybe me-
diated by the induction of TNF and FasL pathways [24–26]
or Fas expression [27].
Furthermore in our report; we revealed that mechanism
of IL-18 inhibitory eﬀect is attributed to the modulation of
cell cycle progression leading to S phase arrest. It has been
demonstrated in several studies that S phase arrest is often
accompanied with the interference of cell cycle control pro-
teins.Forexample,hypoxia-inducedSphasearrestinhuman
breast (T-47D) and cervical (NHIK 3025) cancer cell lines
was paralleled with the down-regulation of cyclin A [28]. A
study on rat ﬁbroblast showed that in a low serum condition,
the cells entered S phase arrest with a decrease cyclin A, cy-
clin B, and cdc2, whereas the level of cyclin D2, cdk4, and
cdk2 persisted at high level [29]. Though the mechanisms in
KB cells have not been elucidated, it is likely that IL-18 signal
transduction may result in interference with the regulation
of the cyclin proteins and/or the replication of chromosome
during S phase. This, therefore, resulted in a transient delay
of a transition of S to M phase, leading to a slow proliferative
rate.
Collectively, our ﬁndings indicate that suppression of KB
cell proliferation was attributed to the modulation of cell cy-
cle progression and not to the induction of cell death. Data
presented in this research could provide an insight on how
oralcarcinomacellsdirectlyrespondtoIL-18asthiscytokine
is an important key regulator of anticancer mechanisms, and6 Mediators of Inﬂammation
this could identify a new role for this cytokine, secondary to
the modulation of the immune response.
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